ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Prospect Capital Corp
25.06
0.0000
成交量:
- -
成交額:
31.97萬
市值:
92.18億
市盈率:
68.17
高:
25.06
開:
25.06
低:
25.06
收:
25.06
52周最高:
26.49
52周最低:
25.00
股本:
3.68億
流通股本:
- -
量比:
- -
換手率:
- -
股息:
0.72
股息率:
2.87%
每股收益(TTM):
0.3676
每股收益(LYR):
0.3948
淨資產收益率:
4.16%
總資產收益率:
4.83%
市淨率:
2.90
市盈率(LYR):
63.48
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
原發性膽汁性膽管炎新藥在海南博鰲樂城獲批
新京报
·
2025/12/24
吉利德:原發性膽汁性膽管炎藥物Seladelpar在海南博鰲樂城獲批
人民财讯
·
2025/12/23
Tharimmune, Inc.盤中異動 早盤股價大漲9.48%報2.54美元
市场透视
·
2025/12/22
Tharimmune, Inc.盤中異動 臨近午盤股價大跌6.46%
市场透视
·
2025/11/12
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PBC"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"PBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","market":"US","secType":"STK","nameCN":"Prospect Capital Corp","latestPrice":25.06,"timestamp":1640811600000,"preClose":25.06,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":367817926,"eps":0.367626,"marketStatus":"退市","change":0,"latestTime":"12-29 16:00:00 EST","open":25.06,"high":25.06,"low":25.06,"amount":319705.1613,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.367626,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":25.06,"dividendRate":0.028731,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","floatShares":0,"roa":"4.83%","roe":"4.16%","lyrEps":0.394789,"shares":367817926,"dividePrice":0.72,"high":25.06,"amplitude":0,"preClose":25.06,"low":25.06,"week52Low":25,"pbRate":"2.90","week52High":26.49,"institutionHeld":0,"latestPrice":25.06,"eps":0.367626,"divideRate":0.028731,"volume":0,"delay":0,"ttmEps":0.367626,"open":25.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBC\",params:#limit:5,,,undefined,":[{"date":"2026-02-09","symbol":"PBC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770670800000,"name":null,"time":"盤後","dateTimestamp":1770613200000,"actualEps":null},{"date":"2025-08-26","symbol":"PBC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756238400000,"name":null,"time":"盤後","dateTimestamp":1756180800000,"actualEps":null},{"market":"US","date":"2021-12-30","symbol":"PBC","reason":null,"defaultRemindTime":1640874600000,"announcedDate":"2021-12-01","type":"delisting","dateTimestamp":1640840400000},{"market":"US","date":"2021-11-30","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1638282600000,"name":"Prospect Capital Corp","recordDate":"2021-12-15","payableDate":"2021-12-01","currency":"USD","type":"dividend","dateTimestamp":1638248400000},{"market":"US","date":"2021-08-31","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1630416600000,"name":"Prospect Capital Corp","recordDate":"2021-09-15","payableDate":"2021-09-01","currency":"USD","type":"dividend","dateTimestamp":1630382400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBC\",market:\"US\",,,undefined,":[{"executeDate":"2019-02-28","recordDate":"2019-03-01","paymentDate":"2019-03-15","value":0.4774306,"currency":"USD"},{"executeDate":"2019-08-29","recordDate":"2019-08-30","paymentDate":"2019-09-15","value":0.4296875,"currency":"USD"},{"executeDate":"2019-11-27","recordDate":"2019-11-29","paymentDate":"2019-12-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":"2020-03-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-05-29","recordDate":"2020-06-01","paymentDate":"2020-06-15","value":0.4296875,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBC\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593424175","title":"原發性膽汁性膽管炎新藥在海南博鰲樂城獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593424175","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593424175?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 14:53","pubTimestamp":1766559180,"startTime":"0","endTime":"0","summary":"新京报讯 12月22日,原发性胆汁性胆管炎药物Seladelpar在海南博鳌乐城国际医疗旅游先行区获批,适用于与熊去氧胆酸联合治疗对UDCA单药应答不佳的PBC成人患者,或作为单药用于治疗无法耐受UDCA的PBC成人患者。该药也是全球首个获批用于治疗原发性胆汁性胆管炎的强效选择性过氧化物酶体增殖物激活受体δ激动剂。原发性胆汁性胆管炎已被纳入我国第二批罕见病目录。谢青表示,Seladelpar以其独特的作用机制为原发性胆汁性胆管炎的治疗带来了突破性变革。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512241356572843238.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512241356572843238.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1766559238168453.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1766559238168453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["PBC"],"gpt_icon":0},{"id":"2593246855","title":"吉利德:原發性膽汁性膽管炎藥物Seladelpar在海南博鰲樂城獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593246855","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593246855?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 10:45","pubTimestamp":1766457935,"startTime":"0","endTime":"0","summary":"【吉利德:原发性胆汁性胆管炎药物Seladelpar在海南博鳌乐城获批】12月22日,吉利德原发性胆汁性胆管炎(PBC)药物Seladelpar在海南博鳌乐城国际医疗旅游先行区获批,适用于与熊去氧胆酸(UDCA)联合治疗对UDCA单药应答不佳的PBC成人患者,或作为单药用于治疗无法耐受UDCA的PBC成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202512233599290123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBC"],"gpt_icon":0},{"id":"2593430618","title":"Tharimmune, Inc.盤中異動 早盤股價大漲9.48%報2.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593430618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593430618?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 22:31","pubTimestamp":1766413907,"startTime":"0","endTime":"0","summary":"北京时间2025年12月22日22时31分,Tharimmune, Inc.股票出现波动,股价快速拉升9.48%。截至发稿,该股报2.54美元/股,成交量21.4924万股,换手率0.61%,振幅2.15%。Tharimmune, Inc.股票所在的生物技术行业中,整体涨幅为0.03%。Tharimmune, Inc.公司简介:Tharimmune Inc 是一家生物技术公司,正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222223147a46ae19c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222223147a46ae19c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","PBC","BK4139"],"gpt_icon":0},{"id":"2582373562","title":"Tharimmune, Inc.盤中異動 臨近午盤股價大跌6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373562?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 00:30","pubTimestamp":1762878642,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日00时30分,Tharimmune, Inc.股票出现异动,股价快速下挫6.46%。Tharimmune, Inc.股票所在的生物技术行业中,整体涨幅为1.24%。Tharimmune, Inc.公司简介:Tharimmune Inc 是一家生物技术公司,正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112003042a49a46ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112003042a49a46ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","BK4139","PBC"],"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PBC\",params:#limit:6,delay:false,,,undefined,":[]}}